Art. 7 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 31 Mar 2004cited 9×

In order to prepare its opinion, the Committee for Medicinal Products for Human Use:

(a)

shall verify that the particulars and documents submitted in accordance with Article 6 comply with the requirements of Directive 2001/83/EC, and shall examine whether the conditions specified in this Regulation for granting a marketing authorisation are satisfied;

(b)

may request that an Official Medicines Control Laboratory or a laboratory that a Member State has designated for that purpose test the medicinal product for human use, its starting materials and, if need be, its intermediate products or other constituent materials in order to ensure that the control methods employed by the manufacturer and described in the application documents are satisfactory;

(c)

may request that the applicant supplement the particulars accompanying the application within a specific time period. Where the said Committee avails itself of this option, the time-limit laid down in Article 6(3), first subparagraph, shall be suspended until such time as the supplementary information requested has been provided. Likewise, this time-limit shall be suspended for the time allowed for the applicant to prepare oral or written explanations.

  • Opinion of Advocate General Saugmandsgaard Øe delivered on 25 July 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and OthersDecision

    The exclusive power that Regulation No 726/2004 confers on the EMA in fact relates only to the evaluations carried out so that the Commission can issue the MA for a medicinal product. [See, in particular, Articles 5 to 9 of Regulation No …

    25 Jul 2018 · 62017CC0029

  • Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision

    In the same opinion, the CHMP, pursuant to Article 7 of Regulation No 726/2004, recommended, by consensus, that a marketing authorisation be granted for Tecfidera. Moreover, on the basis of an examination of the scientific evidence and in …

    5 May 2021 · 62018TJ0611

  • Order of the President of the Court of First Instance of 24 April 2009. Nycomed Danmark ApS v Agence européenne des médicaments (EMEA).Decision

    24 Apr 2009 · 62009TO0052

  • BSG, Urteil vom 29. Juni 2023 - B 1 KR 35/21 RDecision

    29 Jun 2023 · KSRE123960131

  • Judgment of the Court (First Chamber) of 21 November 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and Others.Decision

    Article 4 of the regulation lays down that applications for MA are to be submitted to the European Medicines Agency (EMA). The requirements for the submission and examination of those applications are set out in Articles 5 to 15 of the …

    21 Nov 2018 · 62017CJ0029

  • Judgment of the General Court (Fifth Chamber, Extended Composition) of 24 September 2025. Sanofi BV, anciennement Genzyme Europe BV v EuropeDecision

    On 23 July 2021, the CHMP, pursuant to Article 7 of Regulation No 726/2004, issued an opinion recommending, by consensus, that the Commission grant an MA for Nexviadyme and finding that avalglucosidase alfa was not an NAS (‘the CHMP …

    24 Sep 2025 · 62022TJ0483

  • Opinion of Advocate General Sharpston delivered on 31 January 2013. Novartis Pharma GmbH v Apozyt GmbH.Decision

    Articles 4 to 10 set out the procedure relating to applications for the authorisation of a medicinal product. Applications are to be submitted to the European Medicines Agency established under the Regulation, [See Articles 1 and 4(1).] …

    31 Jan 2013 · 62011CC0535

  • Ordonnance de la Cour (septième chambre) du 3 juillet 2025. UY contre Commission européenne.Decision

    Au soutien de son pourvoi, le requérant soulève deux moyens, tirés, le premier, d’une violation de l’article 18 du statut de la Cour de justice de l’Union européenne, de l’article 47 de la charte des droits fondamentaux de …

    3 Jul 2025 · 62024CO0139

  • Ordonnance de la Cour (septième chambre) du 3 juillet 2025. UY contre Commission européenne.Decision

    Au soutien de son pourvoi, le requérant soulève deux moyens, tirés, le premier, d’une violation de l’article 18 du statut de la Cour de justice de l’Union européenne, de l’article 47 de la charte des droits fondamentaux de …

    3 Jul 2025 · 62024CO0148